Moreover, by analyzing the immunotherapy datasets, we proved that patients with high cuproptosis scores were sensitive to ICI treatment in GSE135222 cohort (Fig. 12A, Advanced non-small cell lung carcinoma, anti-PD-1/PD-L1) and checkmate cohort (Fig. 12B, Kidney renal clear cell carcinoma, anti-PD-1). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.